67 is the total number of securities Bain Capital Life Sciences Investors, LLC has owned. The longest Bain Capital Life Sciences Investors, LLC has owned a single stock is 20 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| APTX | APTINYX INC | 20 | 20 | 0.14% | 3.62% | 16.85% | Q2 2018 | Q1 2023 | 20 |
| SLDB | SOLID BIOSCIENCES INC | 19 | 19 | 0.44% | 5.89% | 22.21% | Q1 2018 | Q3 2022 | 19 |
| SVRA | SAVARA INC | 19 | 19 | 0.37% | 2.95% | 6.44% | Q4 2019 | Q2 2024 | 19 |
| XFOR | X4 PHARMACEUTICALS INC | 19 | 19 | 0.34% | 1.38% | 3.19% | Q4 2019 | Q2 2024 | 19 |
| ARQT | ARCUTIS BIOTHERAPEUTIC... | 18 | 18 | 0.93% | 6.43% | 20.06% | Q1 2020 | Q2 2024 | 18 |
| SWTX | SPRINGWORKS THERAPEUTI... | 17 | 17 | 7.97% | 24.05% | 41.80% | Q3 2019 | Q3 2023 | 17 |
| MRSN | MERSANA THERAPEUTICS, ... | 17 | 17 | 1.23% | 3.95% | 8.44% | Q2 2020 | Q2 2024 | 17 |
| DRNA | DICERNA PHARMACEUTICAL... | 16 | 16 | 3.85% | 25.19% | 58.64% | Q4 2017 | Q3 2021 | 16 |
| DVAX | DYNAVAX TECHNOLOGIES C... | 11 | 5 | 1.51% | 6.88% | 12.42% | Q3 2019 | Q3 2023 | 16 |
| ANNX | ANNEXON INC | 16 | 16 | 0.86% | 3.60% | 9.13% | Q3 2020 | Q2 2024 | 16 |
| AVIR | ATEA PHARMACEUTICALS, ... | 15 | 15 | 0.73% | 4.28% | 19.64% | Q4 2020 | Q2 2024 | 15 |
| NRIX | NURIX THERAPEUTICS, INC. | 15 | 15 | 1.34% | 2.32% | 4.18% | Q3 2020 | Q1 2024 | 15 |
| CCCC | C4 THERAPEUTICS, INC. | 15 | 15 | 0.34% | 2.10% | 4.55% | Q4 2020 | Q2 2024 | 15 |
| PHVS | PHARVARIS N.V. | 14 | 14 | 2.91% | 5.87% | 11.17% | Q1 2021 | Q2 2024 | 14 |
| CRNX | CRINETICS PHARMACEUTIC... | 14 | 14 | 0.93% | 3.35% | 5.40% | Q2 2020 | Q3 2023 | 14 |
| MARINUS PHARMACEUTICAL... | 14 | 14 | 0.29% | 1.15% | 1.68% | Q1 2021 | Q2 2024 | 14 | |
| MRNS | MARINUS PHARMACEUTICAL... | 13 | 13 | 1.10% | 6.34% | 21.30% | Q4 2017 | Q4 2020 | 13 |
| NAUT | NAUTILUS BIOTECHNOLOGY... | 13 | 13 | 0.40% | 0.70% | 1.32% | Q2 2021 | Q2 2024 | 13 |
| NUVALENT INC | 12 | 12 | 4.62% | 12.46% | 25.23% | Q3 2021 | Q2 2024 | 12 | |
| RAPID MICRO BIOSYSTEMS... | 12 | 12 | 0.60% | 3.00% | 9.66% | Q3 2021 | Q2 2024 | 12 | |
| TANGO THERAPEUTICS INC | 12 | 12 | 0.66% | 1.72% | 3.64% | Q3 2021 | Q2 2024 | 12 | |
| INVIVYD INC | 12 | 12 | 0.21% | 1.06% | 6.52% | Q3 2021 | Q2 2024 | 12 | |
| AGLE | AEGLEA BIOTHERAPEUTICS... | 12 | 12 | 0.19% | 1.03% | 2.62% | Q2 2020 | Q1 2023 | 12 |
| XILIO THERAPEUTICS INC | 11 | 11 | 0.15% | 1.05% | 3.56% | Q4 2021 | Q2 2024 | 11 | |
| REPL | REPLIMUNE GROUP INC | 9 | 9 | 4.55% | 9.97% | 21.14% | Q3 2018 | Q3 2020 | 9 |
| 2SEVENTY BIO INC | 9 | 9 | 0.36% | 1.47% | 2.45% | Q4 2021 | Q4 2023 | 9 | |
| EQRX INC | 8 | 8 | 1.92% | 3.80% | 5.91% | Q4 2021 | Q3 2023 | 8 | |
| SYROS PHARMACEUTICALS INC | 8 | 8 | 0.69% | 1.10% | 2.05% | Q3 2022 | Q2 2024 | 8 | |
| BLSA | BCLS ACQUISITION CORP | 8 | 8 | 0.29% | 0.41% | 0.58% | Q4 2020 | Q3 2022 | 8 |
| FLACU | FRAZIER LIFESCIENCES A... | 8 | 8 | 0.17% | 0.25% | 0.36% | Q4 2020 | Q3 2022 | 8 |
| NEWAMSTERDAM PHARMA CO... | 7 | 7 | 10.11% | 14.39% | 22.09% | Q4 2022 | Q2 2024 | 7 | |
| SOLID BIOSCIENCES INC | 7 | 7 | 0.88% | 2.14% | 4.32% | Q4 2022 | Q2 2024 | 7 | |
| SYRS | SYROS PHARMACEUTICALS,... | 7 | 7 | 0.71% | 1.87% | 3.94% | Q4 2020 | Q2 2022 | 7 |
| NEWAMSTERDAM PHARMA CO... | 7 | 7 | 0.01% | 0.04% | 0.10% | Q4 2022 | Q2 2024 | 7 | |
| IFRX | INFLARX NV | 6 | 6 | 11.07% | 20.38% | 31.91% | Q4 2017 | Q1 2019 | 6 |
| CNST | CONSTELLATION PHARMACE... | 6 | 6 | 1.86% | 7.16% | 19.84% | Q4 2019 | Q1 2021 | 6 |
| DISC MEDICINE INC | 6 | 6 | 5.27% | 6.87% | 8.89% | Q1 2023 | Q2 2024 | 6 | |
| CARA | CARA THERAPEUTICS INC | 6 | 6 | 0.00% | 1.78% | 3.24% | Q2 2022 | Q3 2023 | 6 |
| ACRS | ACLARIS THERAPEUTICS INC | 6 | 6 | 0.12% | 1.74% | 3.63% | Q1 2023 | Q2 2024 | 6 |
| RACB | RESEARCH ALLIANCE CORP II | 6 | 6 | 0.58% | 0.79% | 1.15% | Q1 2021 | Q2 2022 | 6 |
| ARYD | ARYA SCIENCES ACQUISIT... | 6 | 6 | 0.42% | 0.56% | 0.80% | Q1 2021 | Q2 2022 | 6 |
| JYAC | JIYA ACQUISITION CORP | 6 | 6 | 0.17% | 0.21% | 0.29% | Q4 2020 | Q1 2022 | 6 |
| NTRA | NATERA INC | 5 | 5 | 2.40% | 4.10% | 6.28% | Q4 2022 | Q4 2023 | 5 |
| CABA | CABALETTA BIO INC | 5 | 5 | 1.36% | 2.80% | 4.35% | Q2 2023 | Q2 2024 | 5 |
| ARYA SCIENCES ACQUISIT... | 5 | 5 | 0.31% | 0.46% | 0.58% | Q3 2021 | Q3 2022 | 5 | |
| PANA | PANACEA ACQUISITION CO... | 5 | 5 | 0.30% | 0.41% | 0.57% | Q2 2021 | Q2 2022 | 5 |
| OMEG | OMEGA ALPHA SPAC | 5 | 5 | 0.22% | 0.28% | 0.38% | Q1 2021 | Q1 2022 | 5 |
| KYMR | KYMERA THERAPEUTICS INC. | 4 | 4 | 1.06% | 1.66% | 2.20% | Q3 2020 | Q2 2021 | 4 |
| THIRD HARMONIC BIO INC | 4 | 4 | 0.32% | 1.59% | 5.16% | Q3 2022 | Q2 2023 | 4 | |
| BLUE | BLUEBIRD BIO, INC. | 4 | 4 | 0.43% | 0.73% | 1.13% | Q1 2021 | Q4 2021 | 4 |
| BCTG | BCTG ACQUISITION CORP | 4 | 4 | 0.32% | 0.46% | 0.69% | Q3 2020 | Q2 2021 | 4 |
| HLXA | HELIX ACQUISITION CORP | 4 | 4 | 0.14% | 0.16% | 0.18% | Q4 2020 | Q3 2021 | 4 |
| AMYLYX PHARMACEUTICALS... | 3 | 3 | 3.44% | 3.76% | 4.40% | Q1 2022 | Q3 2022 | 3 | |
| PTGX | PROTAGONIST THERAPEUTI... | 3 | 3 | 2.10% | 2.42% | 2.88% | Q2 2022 | Q4 2022 | 3 |
| CBAY | CYMABAY THERAPEUTICS INC | 3 | 3 | 1.52% | 2.36% | 2.82% | Q1 2023 | Q3 2023 | 3 |
| ACAD | ACADIA PHARMACEUTICALS... | 3 | 3 | 0.99% | 1.14% | 1.25% | Q2 2022 | Q4 2022 | 3 |
| RACA | THERAPEUTICS ACQUISITI... | 3 | 3 | 0.60% | 0.94% | 1.34% | Q3 2020 | Q1 2021 | 3 |
| ARYA | ARYA SCIENCES ACQUISIT... | 3 | 3 | 0.68% | 0.82% | 1.01% | Q3 2020 | Q1 2021 | 3 |
| DIANTHUS THERAPEUTICS INC | 2 | 2 | 7.21% | 7.89% | 8.56% | Q1 2024 | Q2 2024 | 2 | |
| MDGL | MADRIGAL PHARMACEUTICA... | 2 | 2 | 4.23% | 5.71% | 7.20% | Q4 2023 | Q1 2024 | 2 |
| KYVERNA THERAPEUTICS INC | 2 | 2 | 2.77% | 4.54% | 6.32% | Q1 2024 | Q2 2024 | 2 | |
| SAGE | SAGE THERAPEUTICS, INC. | 2 | 2 | 2.17% | 2.51% | 2.84% | Q2 2020 | Q3 2020 | 2 |
| CTIC | CTI BIOPHARMA CORP | 2 | 2 | 2.47% | 2.50% | 2.54% | Q4 2022 | Q1 2023 | 2 |
| RVMD | REVOLUTION MEDICINES INC | 1 | 1 | 3.06% | 3.06% | 3.06% | Q4 2023 | Q4 2023 | 1 |
| DYNAVAX TECHNOLOGIES CORP | 1 | 1 | 3.04% | 3.04% | 3.04% | Q4 2020 | Q4 2020 | 1 | |
| IPSC | CENTURY THERAPEUTICS INC | 1 | 1 | 1.52% | 1.52% | 1.52% | Q2 2024 | Q2 2024 | 1 |
| PANAU | PANACEA ACQUISITION CORP | 1 | 1 | 0.47% | 0.47% | 0.47% | Q3 2020 | Q3 2020 | 1 |
Download | |||||||||
The securities at the top of the list , including APTINYX INC, SOLID BIOSCIENCES INC, and SAVARA INC, are the highest-conviction holdings of Bain Capital Life Sciences Investors, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Bain Capital Life Sciences Investors, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Bain Capital Life Sciences Investors, LLC owns currently or has owned in the past.